Mcl1 downregulation sensitizes neuroblastoma to cytotoxic chemotherapy and small molecule Bcl2-family antagonists. - Wikidata - wikimedia - TriplyDB

Mcl1 downregulation sensitizes neuroblastoma to cytotoxic chemotherapy and small molecule Bcl2-family antagonists.

Mcl1 downregulation sensitizes neuroblastoma to cytotoxic chemotherapy and small molecule Bcl2-family antagonists.

http://www.wikidata.org/entity/Q37163339

about

CDK Inhibitors Roscovitine and CR8 Trigger Mcl-1 Down-Regulation and Apoptotic Cell Death in Neuroblastoma Cells BET Inhibition Silences Expression of MYCN and BCL2 and Induces Cytotoxicity in Neuroblastoma Tumor Models The combination of BH3-mimetic ABT-737 with the alkylating agent temozolomide induces strong synergistic killing of melanoma cells independent of p53 ABT-737 overcomes resistance to immunotoxin-mediated apoptosis and enhances the delivery of pseudomonas exotoxin-based proteins to the cell cytosol.Identification of BIRC6 as a novel intervention target for neuroblastoma therapy.Overexpression of Mcl-1L splice variant is associated with poor prognosis and chemoresistance in oral cancers.The stress protein BAG3 stabilizes Mcl-1 protein and promotes survival of cancer cells and resistance to antagonist ABT-737 Therapeutic targets for neuroblastomas.Miniature short hairpin RNA screens to characterize antiproliferative drugs Upregulated WDR5 promotes proliferation, self-renewal and chemoresistance in bladder cancer via mediating H3K4 trimethylation.USP9X inhibition promotes radiation-induced apoptosis in non-small cell lung cancer cells expressing mid-to-high MCL1 Radiosensitization by a novel Bcl-2 and Bcl-XL inhibitor S44563 in small-cell lung cancer.Broad targeting of resistance to apoptosis in cancer.How to target apoptosis signaling pathways for the treatment of pediatric cancers Regulation of Transient Site-specific Copy Gain by MicroRNA.YM-155 potentiates the effect of ABT-737 in malignant human glioma cells via survivin and Mcl-1 downregulation in an EGFR-dependent context.BH3 response profiles from neuroblastoma mitochondria predict activity of small molecule Bcl-2 family antagonists.High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibition.Multiple components of the spliceosome regulate Mcl1 activity in neuroblastoma.Neuroblastoma treatment in the post-genomic era.Biomarkers of therapeutic response to BCL2 antagonists in cancer.Involvement of AMP-activated protein kinase in mediating pyrrolo-1,5-benzoxazepine-induced apoptosis in neuroblastoma cells.EGFR signaling defines Mcl⁻1 survival dependency in neuroblastoma.MiR-125a/b regulates the activation of cancer stem cells in paclitaxel-resistant colon cancer.Protective effect of plaunotol against doxorubicin-induced renal cell death.Mitochondrial Bcl-2 family dynamics define therapy response and resistance in neuroblastoma The novel Bcl-2 inhibitor ABT-737 is more effective in hypoxia and is able to reverse hypoxia-induced drug resistance in neuroblastoma cells.Dual targeting of MDM2 and BCL2 as a therapeutic strategy in neuroblastoma.ABT-737, a small molecule Bcl-2/Bcl-xL antagonist, increases antimitotic-mediated apoptosis in human prostate cancer cells Understanding sensitivity to BH3 mimetics: ABT-737 as a case study to foresee the complexities of personalized medicine.Preferential targeting of cancer stem cells in the radiosensitizing effect of ABT-737 on HNSCC.The synergism of MCL1 and glycolysis on pediatric acute lymphoblastic leukemia cell survival and prednisolone resistance.Synergistic cytotoxicity of a prostate cancer-specific immunotoxin in combination with the BH3 mimetic ABT-737.MCL-1 inhibition in cancer treatment Dual BRD4 and AURKA Inhibition Is Synergistic against MYCN-Amplified and Nonamplified Neuroblastoma

P2860

Q27670943-2024848A-AE0C-4B8B-93B0-276362187439 Q27679878-7F89EB01-3E2E-4C21-BF34-8F37922D4F46 Q28476737-D3AB08D8-4AF7-4788-B4DD-CBEDFDAABC38 Q34144923-F6D8DE83-36AD-48F7-B905-CE26BB49B503 Q34334471-B0F38D45-133F-4527-8C39-88C03F79C249 Q34541989-AE59AA8E-34F6-4101-B20C-ADF6DEF9C45D Q34557856-A4630869-BC83-4BCE-AE52-32C891943B6F Q34560877-5F9E8012-92B1-4E1A-AFDC-D244B8CCE035 Q34782184-5E0C66A0-9BFD-4C04-AE52-47644FF52184 Q35056092-EDE6BAAD-2330-4D2F-8FAA-E08BFE1E09EC Q35563248-47012634-6592-4B4C-98D8-4FE26FB63E1B Q35966191-E16FC446-60F9-46EE-AEC3-6FF27834E1E2 Q36483749-5165FCB1-D2A4-4D62-B5D1-8DBCAB5010B9 Q36610528-F6963022-3DDB-42DA-998E-7AE141FDD874 Q36650250-24FA31BE-AE18-41A2-84FD-D0F4DD5064BB Q36681060-632A43F2-5639-498E-8700-EDBF222F1800 Q36948615-90727EFC-98D7-48FD-B60E-F95849B29EF6 Q37317447-CC0F5063-A7A6-49EE-B6D6-2E842DCC96A8 Q37620684-B87EE68E-B972-4D16-B2AA-B1206804C562 Q37633731-FAD8A926-D1A6-4BEC-B215-50FCAC86E3F6 Q38047846-C0C6CC26-3509-40DC-BAB7-B8AD8D7ABE0D Q38849601-5593887E-C64C-4319-86EB-71064DA2DF1B Q38901662-4149F21E-EC8A-4374-8DC4-0EC7BB72DA3C Q39209084-62491CDB-4BDA-45B0-974D-37836CADCB47 Q39321425-7FA561F0-C531-4195-A321-7D3C7A58F721 Q39347735-721F4093-5279-4E05-9253-F3E98B780BF7 Q39456653-BF2BD700-C061-4C81-BAF2-4E70986FE3C4 Q41343291-5F0547E5-1FEE-47EA-8213-3E60D4526FFB Q42094231-CBFBC84D-7731-42C7-A249-9135F66447FA Q42117299-39812BBB-8B46-4C8E-8C95-25D5CA866570 Q42425463-842F7FD4-71F0-4BDE-B3AF-1AB97E6E57CB Q42831411-FF58A335-40F7-481F-B931-AB2A39AF3449 Q47349096-2AF4DC79-65DC-4CBF-8A4B-CF65A84968C4 Q58694408-5A4BFF35-4FA4-48AB-8186-C0A7C90D354B Q58702896-4B0DEA08-1459-44CA-8551-A17FD29CDB70

P2860

Mcl1 downregulation sensitizes neuroblastoma to cytotoxic chemotherapy and small molecule Bcl2-family antagonists.

http://www.wikidata.org/entity/Q37163339

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 08 August 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Mcl1 downregulation sensitizes ...... ecule Bcl2-family antagonists.

@en

Mcl1 downregulation sensitizes ...... ecule Bcl2-family antagonists.

@nl

type

label

Mcl1 downregulation sensitizes ...... ecule Bcl2-family antagonists.

@en

Mcl1 downregulation sensitizes ...... ecule Bcl2-family antagonists.

@nl

prefLabel

Mcl1 downregulation sensitizes ...... ecule Bcl2-family antagonists.

@en

Mcl1 downregulation sensitizes ...... ecule Bcl2-family antagonists.

@nl

P1433

Q37163339-BD4B3C16-6710-4FE0-AFD0-D6986A7507C4

P1476

Q37163339-C00520DD-DB85-48BB-8B2B-12EF91CA3860

P2093

Q37163339-17870F68-40EB-4D38-ACD4-F573E8CC451E

Q37163339-1BBFB7B7-39B5-408A-BDAE-C59FA56D7DCB

Q37163339-5B3A7010-A31A-4990-A5D4-797FDD1D2D71

Q37163339-8F51646C-C4F6-441D-B532-95BE098DD010

Q37163339-9B106EF3-037D-49D7-A14D-CC26EA7BA39E

Q37163339-DE607B7E-CCF0-4A48-B9C4-68E5E203F1D9

Q37163339-F50687BB-100B-4181-9D30-1A3406B3E714

P2860

Q37163339-00A059F8-D0F9-4221-9DEF-B13ABA85770B

Q37163339-00D5AC2A-01B2-4F78-87DC-F429C6312141

Q37163339-05B4119D-4A34-4403-BFA9-E72BF506490E

Q37163339-09D4B38B-CCEF-4B23-943A-514448D1E3C6

Q37163339-13DE1B08-6A2C-493B-A1FA-7D04332CA51B

Q37163339-1678396E-FC2C-40CF-84B3-D5C744C27DAE

Q37163339-2E83C535-9457-4687-A96F-A6F0FDBC9839

Q37163339-3041F5D7-D3FD-453B-8AE1-2BDA55FFF78F

Q37163339-3E209831-93B6-4EDE-A02A-A106D4ACA24B

Q37163339-44EDEE33-0750-4DF3-9D97-0EA72283492A

P304

Q37163339-D98F867A-E58D-4366-A866-D5BDF2C6E095

P31

Q37163339-9FBBEACD-0BD0-4C7E-BA3A-597C94C8B17F

P356

Q37163339-970C1883-CA4B-4D26-977F-30792976F01A

P433

Q37163339-BEC7A0A3-9858-4EE8-8258-BCE9CA9A4595

P478

Q37163339-5BD0498C-6746-44F3-AB0D-233A153D8E4C

P50

Q37163339-60064CA0-99A5-4B48-8F50-3D146715BAD7

P577

Q37163339-F680CE9F-2868-4599-A2EE-BAE6BB3E1EA4

P5875

Q37163339-A596A42C-946D-480D-A652-1C05238529A4

P698

Q37163339-B7ECAA94-977D-4C72-A469-C7FEF1B8B70E

P921

Q37163339-40365AB1-2094-4B14-94A0-2BD5E15A0387

Q37163339-EFB86BA3-5285-43CD-AAE8-650BF17895C1

P932

Q37163339-AC52AD9F-60EC-4C5C-9CBD-ED93536CCAF2

P356

P1433

Cancer Biology and Therapy

P1476

Mcl1 downregulation sensitizes ...... lecule Bcl2-family antagonists

@en

P2093

Bella Goyal

http://www.w3.org/2001/XMLSchema#string

Brian J Lestini

http://www.w3.org/2001/XMLSchema#string

Bruce R Pawel

http://www.w3.org/2001/XMLSchema#string

Kelly C Goldsmith

http://www.w3.org/2001/XMLSchema#string

Mark N Fluchel

http://www.w3.org/2001/XMLSchema#string

Michael D Hogarty

http://www.w3.org/2001/XMLSchema#string

Xueyuan Liu

http://www.w3.org/2001/XMLSchema#string

P2860

Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia

Identification of ALK as a major familial neuroblastoma predisposition gene

FKHRL1-mediated expression of Noxa and Bim induces apoptosis via the mitochondria in neuroblastoma cells

ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor

'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737.

Induction of Noxa sensitizes human colorectal cancer cells expressing Mcl-1 to the small-molecule Bcl-2/Bcl-xL inhibitor, ABT-737.

Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma.

Overall genomic pattern is a predictor of outcome in neuroblastoma.

The requirement for evasion of programmed cell death in neuroblastomas with MYCN amplification.

Targeting programmed cell death pathways with experimental therapeutics: opportunities in high-risk neuroblastoma.

P304

1587-1595

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4161/CBT.8.16.8964

http://www.w3.org/2001/XMLSchema#string

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-08-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26321121

http://www.w3.org/2001/XMLSchema#string

P698

19556859

http://www.w3.org/2001/XMLSchema#string

P921

P932

3770183

http://www.w3.org/2001/XMLSchema#string